Literature DB >> 22550982

New and emerging treatments for Alzheimer's disease.

Anne Corbett1, Jessica Smith, Clive Ballard.   

Abstract

Alzheimer's disease (AD) and other dementias represent a significant and increasing clinical challenge. This review highlights current treatment options for AD and the main focusses of therapies currently being evaluated in clinical trials and for future therapeutic development. Existing treatments slow the progression of symptoms of the disease, but their efficacy does not extend to all people with AD, and benefits are not conveyed beyond an average of 6 months. Despite the substantial economic cost and healthcare burden of AD, which is increasing as populations age, there are currently only three therapies being investigated in Phase III clinical trials. This emphasises the substantial caution and underinvestment in treatment development in this area and why it is critical to address the current lack of effective treatments to target the underlying pathology and disease process in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22550982     DOI: 10.1586/ern.12.43

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  14 in total

Review 1.  Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease.

Authors:  David A Bennett; Lei Yu; Philip L De Jager
Journal:  Biochem Pharmacol       Date:  2014-02-06       Impact factor: 5.858

Review 2.  Functional analyses of major cancer-related signaling pathways in Alzheimer's disease etiology.

Authors:  Jianping Guo; Ji Cheng; Brian J North; Wenyi Wei
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-07-08       Impact factor: 10.680

3.  Heat shock proteins regulate activation-induced proteasomal degradation of the mature phosphorylated form of protein kinase C.

Authors:  Michelle A Lum; Gregor M Balaburski; Maureen E Murphy; Adrian R Black; Jennifer D Black
Journal:  J Biol Chem       Date:  2013-07-30       Impact factor: 5.157

Review 4.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

5.  Neurotransmitter receptor and time dependence of the synaptic plasticity disrupting actions of Alzheimer's disease Aβ in vivo.

Authors:  Igor Klyubin; Tomas Ondrejcak; Jennifer Hayes; William K Cullen; Alexandra J Mably; Dominic M Walsh; Michael J Rowan
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-12-02       Impact factor: 6.237

Review 6.  Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer.

Authors:  Patrycja Nowak-Sliwinska; Leonardo Scapozza; Ariel Ruiz i Altaba
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-04-26       Impact factor: 10.680

Review 7.  Brain "fog," inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolin.

Authors:  Theoharis C Theoharides; Julia M Stewart; Erifili Hatziagelaki; Gerasimos Kolaitis
Journal:  Front Neurosci       Date:  2015-07-03       Impact factor: 4.677

Review 8.  Mitochondrial mechanisms of neuroglobin's neuroprotection.

Authors:  Zhanyang Yu; Jessica L Poppe; Xiaoying Wang
Journal:  Oxid Med Cell Longev       Date:  2013-03-24       Impact factor: 6.543

9.  An enzyme-generated fragment of tau measured in serum shows an inverse correlation to cognitive function.

Authors:  Kim Henriksen; Yaguo Wang; Mette G Sørensen; Natasha Barascuk; Joyce Suhy; Jan T Pedersen; Kevin L Duffin; Robert A Dean; Monika Pajak; Claus Christiansen; Qinlong Zheng; Morten A Karsdal
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

Review 10.  Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders.

Authors:  Hyeong-Min Lee; Yuna Kim
Journal:  Schizophr Res Treatment       Date:  2016-03-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.